Clinical trial
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage…
NCT00293332 · University of California, San Francisco, Other · Terminated
Key facts
| NCT number | NCT00293332 |
|---|---|
| Title | Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery |
| Official title | A Phase II Study of Neoadjuvant Therapy With Docetaxel, Carboplatin, and Bevacizumab in Patients With Resectable Early Stage Non-Small Cell Lung Cancer |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | bevacizumab, carboplatin, docetaxel, conventional surgery |
| Enrollment | 1 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Feb 17, 2006 |
| Last update posted | Feb 9, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: